$1.48
+0.14 (+10.45%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where OCGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 2 expanded access · 3 with posted results
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, Qube Research & Technologies Ltd, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +4 more) · FINRA short interest 21.6 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMDNCT07770828Rate of change (slope) of square root-transformed GA lesion area from baseline to Month 12Randomized · Single-masked · Treatment | Phase 3 | Recruiting | Biological: OCU410 | Dry Age-related Macular Degeneration | 237 | 2028-07-30 | in 710 d | 2026-08-19 |
| Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisNCT05203939Study Drug-related adverse events (SDAE)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing | Retinitis Pigmentosa, Leber Congenital Amaurosis | 22 | Mar 2027 | ≤ 223 d | 2026-07-31 |
| A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated controlRandomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Genetic: Sub-Retinal Administration of OCU400-301 | Retinitis Pigmentosa | 140 | 2027-02-12 | in 176 d | 2026-07-31 |
| A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626Change from baseline in atrophic lesion size as measured by Fundus Auto FluorescenceRandomized · Single-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: OCU410ST | Stargardt Disease | 51 | 2026-09-28 | in 39 d | 2026-07-31 |
| Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)NCT05802329Study Drug-related adverse events (SDAE)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: OCU200 | Center Involved Diabetic Macular Edema, Diabetic Macular Edema | 24 | 2026-07-31 | — | 2026-07-31 |
| Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyNCT06018558Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))Randomized · Single-masked · Treatment | Phase 1/2 | Active, not recruiting | Genetic: OCU410 | Geographic Atrophy | 60 | 2026-02-03actual | — | 2026-07-31 |
| Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy AdultsNCT05258669Compare immune response measured by serum neutralizing antibodies against Wild-Type SARS-CoV-2 in US-based participants and age-matched controls participants who participated in the Phase 3 efficacy trial in India.Randomized · Quadruple-masked · Prevention | Phase 2/3 | Unknown status | Biological: BBV152 | COVID-19 | 400 | 2023-09-01 | — | 2023-03-27 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host DiseaseNCT03591874results2022-07-06Change From Baseline to Day 84 in Validated Bulbar Redness (VBR) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Primary endpoint was not met. | Drug: Brimonidine Tartrate, Placebos | Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease | 59 | 2020-04-30actual | — | 2022-07-06 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)NCT03785340results2022-06-06Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol, Statistical Analysis Plan, and Informed Consent Form ↗ | Phase 3 | Completed | Drug: Brimonidine Tartrate, Placebos | Dry Eye | 252 | 2019-02-25actual | — | 2022-07-18 |
| Dry Eye Disease Study With BrimonidineNCT03418727results2022-07-06Tolerance of Test Substance Visual Analogue Scale (VAS) ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop | Dry Eye | 84 | 2018-03-29actual | — | 2022-07-06 |
| Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and OlderNCT05541289expanded access | — | No longer available | Biological: BBV152 | COVID-19 | — | — | — | 2022-09-22 |
| Expanded Access Program for RP in AdultsNCT06574997expanded access | — | No longer available | Drug: OCU400 | Retinitis Pigmentosa | — | — | — | 2026-07-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19